drugset / Trial / NCT00217178
Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)
Phase 4
Unknown
900 enrolled
Hamilton Health Sciences Corporation
Canadian Institutes of Health Research (CIHR) · collabPopulation Health Research Institute · collab
RandomizedFactorialDouble-blindPrevention
Summary
Study Objective: 1\. To evaluate whether combined therapy with folic acid 2.5 mg/day, vitamin B6 50 mg/day and vitamin B12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progression, as evaluated by quantitative B-mode carotid ultrasound (US).
Timeline
- Start
- 2000-01
- Primary completion
- —
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B12 | Other / unclassified | 1000 ug | — |
| Subject | B6 | Other / unclassified | 50 mg | — |
| Subject | folic acid | Other / unclassified | 2.5 mg | — |